Take a closer look at HD-MDS and AML in this video
Learn more about what patients and health care professionals face with these conditions.
The TIM-3 receptor is expressed on immune cells as well as leukemic stem cells (LSCs) and blast cells but not on normal hematopoietic stem cells.3-9
- TIM-3 is a key regulator of innate and adaptive immune responses10
Opportunity to activate (turn up) immune response
- When TIM-3 binds to its cognate ligand, components of the immune response may be suppressed1,2,9
- Based on preclinical models, preventing TIM-3 from fulfilling this function could limit these effects and increase an antitumor immune response3
Opportunity to suppress (turn down) leukemic cell proliferation
- TIM-3 is preferentially expressed on LSCs and blast cells, which enables these cells to overproliferate and evade detection by the immune system1,8,9
Clinical significance has not yet been established and research is ongoing.
Watch a video about
The role of TIM-3
Go further in-depth on the role and opportunity of TIM-3 in HR-MDS and AML